Recombinant Human Thrombopoietin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Recombinant Human Thrombopoietin
- Accession Number
- DB16364
- Description
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.1,2 This drug is used in the treatment of thrombocytopenia.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- rhTPO
- rHuTPO
- External IDs
- Recombinant Human Thrombopoietin
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Recombinant human thrombopoietin has similar biological functions as endogenous thrombopoietin.2 It activates the thrombopoietin receptor MPL.1 This therapy has potential roles in hematopoietic stem and progenitor cell regeneration and is currently being investigated against relapsed immune thrombocytopenia, hematopoietic injury, and acute severe thrombocytopenia in sepsis.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Wang C, Zhang B, Wang S, Zhang J, Liu Y, Wang J, Fan Z, Lv Y, Zhang X, He L, Chen L, Xia H, Li Y, Pei X: Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation. Sci Rep. 2015 Sep 25;5:12993. doi: 10.1038/srep12993. [PubMed:26403418]
- Zhou Z, Feng T, Xie Y, Huang P, Xie H, Tian R, Qian B, Wang R: The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis. 2019 Sep 6;19(1):780. doi: 10.1186/s12879-019-4388-2. [PubMed:31492102]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Thrombocytopenia 1 4 Recruiting Treatment Primary Immune Thrombocytopenia 1 4 Recruiting Treatment Thrombocytopenia 1 4 Unknown Status Treatment Allogeneic peripheral haematopoietic stem cell transplant / Delayed Platelet Engraftment / Myeloablative 1 3 Completed Prevention Sarcomas 1 3 Completed Treatment Hematologic Diseases / Thrombocytopenia 1 3 Completed Treatment Idiopathic Thrombocytopenic Purpura / Purpura 3 3 Completed Treatment Immune Thrombocytopenia 1 3 Completed Treatment Immune Thrombocytopenia / Pregnant State 1 3 Not Yet Recruiting Treatment Immune Thrombocytopenia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 17, 2020 15:51 / Updated on December 19, 2020 20:42